PM holds virtual meet with teams developing, manufacturing Covid-19 vaccine

The teams were from Gennova Biopharmaceuticals Ltd in Pune, Biological E Ltd and Dr Reddys Laboratories Ltd in Hyderabad.

Prime Minister Narendra Modi
File photo of Prime Minister Narendra Modi
Press Trust of India New Delhi
2 min read Last Updated : Nov 30 2020 | 3:09 PM IST

Prime Minister Narendra Modi on Monday held a virtual meeting with three teams working on developing and manufacturing COVID-19 vaccine, and said they should take extra efforts to inform people in simple language about the vaccine and related matters such as its efficacy.

A statement from the Prime Minister's Office said that Modi also asked the companies, represented by these teams, to come out with their suggestions and ideas regarding the regulatory processes and related matters.

"The PM advised all the departments concerned to engage with the manufacturers and seek to resolve matters so that the efforts by these companies bear fruit in order to serve the needs of the country and the entire world," it added.

These teams were from Gennova Biopharmaceuticals Ltd Pune, Biological E Ltd Hyderabad and Dr Reddys Laboratories Ltd Hyderabad.

The prime minister appreciated the efforts being taken by scientists in these companies to come out with a vaccine solution to tackle COVID-19.

The potential of various platforms for vaccine development was also discussed, the statement said.

Matters relating to logistics, transport, cold chain etc in respect of delivering the vaccines were also discussed.

All the vaccine candidates discussed are at different stages of trials and detailed data and results are expected early next year onwards, it added.

Modi had on Saturday visited Ahmedabad, Hyderabad and Pune to review the development and manufacturing process of coronavirus vaccines at facilities in these cities.

The total coronavirus cases in India have mounted to 94,31,691 with 38,772 new infections, while the death toll climbed to 1,37,139 after 443 more fatalities were reported, according to Health Ministry data.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus VaccineNarendra ModiDr Reddy's Laboratories Limited

First Published: Nov 30 2020 | 1:54 PM IST

Next Story